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CHAPTER 1 
Introduction 
 
Toxoplasma gondii: a model apicomplexan 
 
Toxoplasma is a protozoan parasite often used as a model system to study the 
biology of other protozoa in its phylum, the Apicomplexa [1]. There are almost 5,000 
different species in the phylum Apicomplexa. Apicomplexan parasites are characterized 
by a polarized cell structure with two unique apical secretory organelles named 
micronemes and rhoptries. These organelles are responsible for parasite adhesion and 
invasion. Other members of the phylum include Plasmodium, the causative agent of 
malaria; Eimeria, which causes coccidiosis in poultry; and Cryptosporidium, which is 
another important opportunistic pathogen of AIDS patients. Unlike most other 
apicomplexans, Toxoplasma is easy to culture in the laboratory and is amenable to 
genetic manipulation. Experimental advantages include the ability to make transgenic 
parasites, including gene fusion, knockouts, or stable ectopic expression. The genome 
sequence is available from the Toxoplasma online database (http://toxodb.org/toxo/), 
facilitating molecular cloning and gene analyses. Additionally, there is a well-established 
mouse animal model to investigate Toxoplasma pathogenesis and host responses. 
Studies in Toxoplasma can facilitate our understanding of apicomplexan pathogenesis, 
so as to contribute to drug development against this phylum of parasites. 
 
Life cycle of Toxoplasma gondii  
      
Toxoplasma gondii is an obligate, intracellular parasite that causes 
toxoplasmosis. This parasite has the ability to infect almost all warm-blooded animals, 
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including humans and livestock. This protozoan parasite occurs worldwide and is 
estimated to infect approximately one-third of the world’s population [2]. Toxoplasma has 
a complex life cycle consisting of a sexual cycle in its definitive host and an asexual 
cycle in its intermediate hosts. The sexual replication of the parasites can only take 
place in the intestine of felids, its definitive host, which excrete oocysts into the 
environment during infection [3]. Once exposed to the environment, sporulation of 
oocysts occurs, resulting in the formation of highly infectious sporozoites. Sporulated 
oocysts contaminate the environment, including soil and water, and can persist in the 
environment for up to 18 months [4]. An intermediate host can be infected by consuming 
undercooked meat of infected animals or water that contains oocysts [5]. If an animal 
consumes oocysts, sporozoites inside the oocysts will invade the epithelial cells of the 
intestine and then differentiate into tachyzoites, the rapidly replicating form of the 
parasites.  
Tachyzoites are capable of infecting any nucleated cell and are responsible for 
tissue destruction. Tachyzoites divide asexually through a process called endodyogeny. 
The parasites keep replicating within the host cell vacuole with a generation time of 6-8 
hours until they break the host cell and egress [6]. The parasites then invade and 
replicate within neighboring host cells. The replication of tachyzoites creates the acute 
phase of toxoplasmosis. The differentiation of tachyzoites to bradyzoites happens 7-10 
days post-infection. Bradyzoites cause chronic infection by forming cysts in tissues, such 
as the central nervous system and muscle tissues. Tissue cysts can protect the 
parasites from the immune system, and as a consequence they can reside in host 
tissues for life. Humans can be infected by bradyzoites by ingesting undercooked meat. 
The cyst wall can be degraded by the digestive enzymes, causing bradyzoite release. 
The bradyzoites then invade the intestinal cells and differentiate back into tachyzoites. 
The reactivation of the parasites is normally prevented by the host immune response. 
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However, in immunocompromised individuals, reactivation of infection is continuous, 
therefore resulting in life-threatening damage to sensitive tissues.  
 
 
 
    
 
  
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Life cycle and transmission of Toxoplasma gondii. 
The sexual cycle of Toxoplasma starts with its definitive host, the cat. Sexual 
reproduction of the parasites results in the formation of oocysts, which will be shed into 
the environment through cat feces. Oocysts are highly infectious and can infect almost 
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all warm-blooded animals. Humans can become infected by consuming undercooked 
meat, contaminated water, or unwashed fruits and vegetables. After entering the host, 
oocysts will form tachyzoites, which will cause acute infection. Stress from the host 
immune response will induce tachyzoites to differentiate into bradyzoites. Bradyzoites 
form tissue cysts and can cause chronic infection. 
 
Toxoplasmosis and treatments 
 
Toxoplasmosis, caused by Toxoplasma, is a severe and life-threatening disease 
in immunocompromised patients and in developing fetuses. Under normal conditions, 
infection by Toxoplasma is asymptomatic. However, in immunocompromised individuals, 
such as AIDS patients, organ transplant recipients, and patients undergoing 
chemotherapy, reactivation of Toxoplasma can cause encephalitis, neurological 
disorders, and even death [7, 8]. Congenital toxoplasmosis is caused by vertical 
transmission of the parasites from a pregnant woman to her fetus, who may develop 
symptoms including deafness, chorioretinitis, and developmental delay [9]. Though this 
pathogen has developed a worldwide prevalence, there is still no vaccine available for 
humans. A combination therapy of pyrimethamine and sulfonamides is the standard 
treatment for toxoplasmosis. Current treatments have certain limitations, such as a 
narrow therapeutic window of pyrimethamine and allergic reactions caused by 
sulfonamides. Pyrimethamine may also cause bone marrow suppression and 
megaloblastic anemia [10]. Allergic reactions associated with sulfonamides include skin 
rashes and epidermal necrosis. More importantly, current available drugs can only 
eliminate tachyzoites but cannot act against bradyzoites. AIDS patients and immune-
compromised patients have to be placed on long-term prophylaxis treatment to prevent 
the reactivation of bradyzoites to tachyzoites. Pyrimethamine is not a safe drug for 
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pregnant women due to its teratogenic effects. The preferred treatment is spiramycin, 
which is unable to cross the placenta, but is believed to block vertical transmission. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Treatment of toxoplasmosis.  
The current treatment for toxoplasmosis is a combination of pyrimethamine and 
sulfonamides. Pyrimethamine, as a competitive inhibitor of Toxoplasma dihydrofolate 
reductase (DHFR), can cause adverse side effects because it is only six times as 
selective for the protozoal form of the enzyme over the mammalian form [11]. 
Sulfonamides targets dihydropteroate synthetase, an enzyme not found in mammalian 
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cells, but the patients usually develop severe allergic reactions [10]. These two drugs 
directly affect parasite amino acid synthesis pathways.  
 
Lysine acetylation and lysine acetyltransferase (KAT) 
 
Acetylation transfers an acetyl group from acetyl coenzyme A to the epsilon-
amino group of a lysine residue, thus neutralizing the positive charge of lysine. This 
process is catalyzed by lysine acetyltransferases (KATs) and reversed by lysine 
deacetylases (KDACs). In 1996, Allis et al discovered the first KAT, GCN5, and the first 
KDAC, HDAC1, both of which were suggested to control transcription through 
acetylating histones [12, 13, 38]. Since then, a great deal of progress has been made to 
understand the roles of acetylation in transcription regulation, nucleosome remodeling, 
and chromatin assembly. When GCN5 histone acetyltransferases were found to have 
non-histone substrates as well, they became referred to as lysine (K) acetyltransferases 
(KATs) [40]. Global lysine acetylation analysis has been applied to different species from 
human cells, plants, Drosophila, lower eukaryotes, and bacteria. Using a human acute 
myeloid leukemia cell line, the Mann group identified 3600 lysine acetylation sites on 
1750 proteins [14]. In E. coli, 1070 acetylation sites on 349 acetylated proteins were 
identified [15]. The Choudhary group identified 1981 lysine acetylation sites in the 
proteome of Drosophila. In Arabidopsis, 91 lysine acetylation sites on 73 proteins of 
diverse functional classes were identified. Our lab identified over 700 lysine acetylation 
sites on a wide variety of parasite proteins in Toxoplasma [17]. These “acetylome” 
studies have expanded our understanding of cellular signaling, suggesting that 
acetylation plays key roles in cytoplasmic functions in addition to well-characterized 
nuclear functions. Acetylation preferentially targets large macromolecular complexes and 
is suggested to play conserved functional roles during evolution [14].       
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Acetylation regulates transcription through modifying the amino-terminal tails of 
histones. Histone proteins and DNA are major components of chromatin existing in 
eukaryotic cell nucleus. The nucleosome, the basic repeating unit of chromatin, consists 
of 146bp of DNA wrapped around a histone octamer with two copies of H2A, H2B, H3, 
and H4. Nucleosomal DNA is generally repressive to transcription. However, acetylation 
increases the decompaction of chromatin by loosening the histone tail - DNA binding. 
The dynamic acetylation state of histone tails enhances transcription factor access [18, 
19]. Many KAT and KAT-containing complexes have been demonstrated to function in 
transcriptional activation. Nuclear KATs can be divided into five families, GCN5-related 
N-acetyltransferases (GNATs); the MYST (for ‘MOZ, Ybf2/Sas3, Sas2 and Tip60’)-
related KATs; p300/CREB binding protein (CBP) KATs; the general transcription factor 
KATs including the TFIID subunit TBP-associated factor-1 (TAF1); and the nuclear 
hormone-related KATs, SRC1 and ACTR (SRC3) [20]. Other than transcription, recent 
data suggests acetylation is a common modification on proteins involved in other nuclear 
processes, such as splicing, cell cycle, chromatin remodeling, DNA replication, and 
nuclear transport [14].  
Our laboratory first produced the proteome-wide analysis of acetylation for 
Toxoplasma. Over 700 novel acetylation sites were detected on a wide variety of 
proteins, mostly involved in metabolism, translation, chromatin biology, and stress 
response. The Sullivan laboratory discovered K23, K79 on histone H3 and K31 on 
histone H4, as novel acetylation marks in Apicomplexa. In addition to histones, we also 
discovered acetylation sites on many KATs in Toxoplasma. The two members of GCN5 
family, TgGCN5-A and TgGCN5–B both are acetylated. TgGCN5-A is acetylated at its 
bromodomain, which is responsible for binding to acetylated lysine [16]. TgGCN5-B is 
highly acetylated at its unique C terminal-tail. MYST family KATs, TgMYST-A and -B, are 
also acetylated. They exist in long and short forms in the parasites. Both TgMYST-A and 
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TgMYST –B are acetylated within the N-terminal extension of the long form of the 
protein. TgMYST-A is also acetylated at its catalytic domain. Moreover, acetylation is 
detected on proteins unique to Apicomplexa, such as Aptela-2 (AP2) domain containing 
proteins and rhoptry proteins. Interestingly, 32% of the acetylome proteins are parasite 
specific, implying a potential role of lysine acetylation as novel drug target.   
 
Histone acetylation and diseases 
 
The competing actions of KAT and KDAC create a balance of acetylation and 
deacetylation capable of nimble responses to environmental factors. Acetylation by 
KATs neutralizes the positive charge of lysine on histones, decreasing the ionic 
interaction between the positively charged histones and negatively charged DNA; the 
action of KATs therefore leads to less compact chromatin. Loose chromatin is more 
accessible to transcription machinery. HDACs regulate chromatin structure in a reverse 
way. Any imbalance of this process may lead to a dysfunction of transcription, DNA 
repair, recombination, and replication. In recent years, there has been significant growth 
in our knowledge about the involvement of abnormal histone acetylation patterns in 
diseases.     
Abnormal histone acetylation has been linked to tumor development due to the 
aberrant transcription of genes regulating important functions such as proliferation, cell 
cycle, and apoptosis. Several events can result in abnormal acetylation patterns: 
changes in KATs or KDACs activities; changes in expression levels of KATs or KDACs; 
altered interactions with other proteins such as transcription factors. Studies of human 
cancers, such as skin cancer and gastrointestinal cancers, suggest a decrease of global 
acetylation, especially on histone H3 and H4 [21, 22]. These changes can be caused by 
a decrease in KAT activity or an increase in HDAC activity. Changes of HDAC 
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expression levels occur in different cancers. For example, there is an increase in HDAC1 
expression in gastric and prostate cancers [23, 24]. Overexpression of HDAC2 has been 
found in cervical and gastric cancers [25, 26]. There are studies indicating that HDACs 
can directly interact with transcription factors such as E2f, Stat3, p53, NF-kB, whose loss 
of functions have been observed in many tumors and have attracted attention as drug 
targets in treating cancers [27]. There are few reports directly implicating the roles of 
KATs in cancers. Some members of MYST KAT family have been suggested to exist in 
the complex with ING tumor suppressor family [28]. 
KATs and KDACs also play important roles in neurodegenerative disorders, such 
as Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease [29]. During 
neurodegenerative conditions, acetylation homeostasis is disrupted. The best studied 
KAT in neurodegeneration diseases is CBP. Several observations indicate that neurons 
are losing CBP and p300 KATs during neurodegeneration. On the other hand, 
overexpression of CBP increases neuronal viability [30, 31]. Various mechanisms behind 
the loss of acetylation homeostasis are known. An increase of proteosomal degradation 
of CBP has been reported in several neurodegenerative diseases [31]. Additionally, 
caspase -6-dependent CBP proteolysis is another mechanism to compromise the normal 
function of CBP [30]. Also, CBP is seen to be relocated into Huntington aggregates, thus 
having trouble to function properly in the nucleus [32]. Studies also suggest that HDAC 
inhibitors, like TSA and suberoylanilide hydroxamic acid (SAHA), may prevent neuronal 
apoptosis during oxidative stress [33].   
 
Autoacetylation of KATs 
 
Recently, global acetylation data indicates most subunits of KAT complexes are 
acetylated. Interestingly, many known KATs are acetylated themselves [34, 35, 36, 37]. 
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A possible mechanism is KAT autoacetylation, and this may be a means to regulate its 
own function. Recently, there are some reports about KAT autoacetylation. The catalytic 
activity of KAT can be regulated by autoacetylation at certain active site lysine residues. 
For example, mutation of K274 to Arg on MOF, a MYST KAT, almost completely 
abolishes its acetylation activity on H4 [34]. Autoacetylation of Rtt109, an ortholog to 
p300 KAT, happens at K290. Autoacetylation stimulates Rtt109 KAT activity by 
increasing acetyl-CoA binding affinity [35]. PCAF, a homolog of GCN5, is acetylated 
within the nuclear localization signal. Catalytically inactive forms of PCAF accumulate in 
the cytoplasm, indicating that autoacetylation may control PCAF nuclear translocation 
[36]. Tip60, a member of MYST family, regulates its dissociation of oligomer and 
interaction with substrates through an autoacetylation mechanism [37]. Our acetylome 
data revealed that TgGCN5-B is acetylated at K857, within the putative ADA2-binding 
domain, and at three lysines at C-terminus. Our lab has identified four acetylated lysines 
on TgGCN5-B, K857, K989, K997 and K1027.  
 
Toxoplasma GCN5 KATs  
 
Lysine acetylation on histones is a well-characterized post-translational 
modification linked to the activation of gene expression. GCN5 is a highly conserved 
catalytic component present in multiple protein complexes linked to the regulation of 
gene expression [39]. The number of GCN5 KATs and their impact on cells or organisms 
depends on the species. GCN5 generally appears to be required for stress responses 
[41, 42, 43]. Consistent with this idea, the single GCN5 is dispensable in 
Saccharomyces cerevisiae, but required for growth on minimal media [44]. In contrast, 
mammals possess two GCN5 family members, only one of which is required for mouse 
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embryogenesis [45]. Null mutants of PCAF, have no discernible phenotype in mice [45, 
46]. 
The relevance of lysine acetylation in pathogenic protozoa is underscored by 
potent antiprotozoal activity of lysine deacetylation inhibitors like apicidin and FR235222 
[47, 48]. Histone acetylation has also been linked to a number of processes that underlie 
pathogenesis of apicomplexan parasites, including antigenic variation in Plasmodium 
(the protozoan causing malaria) or developmental transitions in Toxoplasma gondii, 
which can cause congenital birth defects or life-threatening opportunistic infections in 
immunocompromised individuals [62, 49, 50]. An extensive repertoire of histone 
modification machinery is present in these parasites, suggesting that epigenetic-based 
regulation contributes to gene expression control [51]. A related oddity regarding 
regulation of gene expression in Apicomplexa is that these early-branching eukaryotes 
appear to use an expanded lineage of so-called Apetela-2 (AP2) proteins as 
transcription factors rather than the master regulators conserved throughout most of the 
eukaryotic kingdom [52, 53]. AP2 proteins harbor a plant-like DNA-binding domain and 
emerging evidence supports that at least some of them function as bona fide 
transcriptional regulators [54, 55]. 
Toxoplasma has a number of unusual features with respect to its GCN5 KATs. 
First, there are two GCN5-family members in Toxoplasma (TgGCN5-A and –B) whereas 
other invertebrates, including Plasmodium, possess only one [56, 57]. Second, both 
TgGCN5s have long N-terminal extensions devoid of known protein domains. These N-
terminal extensions are not homologous to those seen in higher eukaryotes, nor are they 
homologous to each other or other apicomplexan GCN5s [57]. One function of the 
GCN5 N-terminal extensions is to translocate the KAT into the parasite nucleus via a 
basic-rich nuclear localization signal [58, 59]. Yeast two-hybrid studies have suggested 
that the N-terminal extension of Plasmodium GCN5 plays a major role in mediating 
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protein-protein interactions [60]. We previously generated a gene knockout of TgGCN5-
A, but similar methods have not produced viable TgGCN5-B knockouts. TgGCN5-A was 
found to be dispensable for parasite proliferation in vitro, but required for the parasite to 
respond properly to alkaline stress [42]. These findings are consistent with the well-
documented role of GCN5 KATs in the cellular stress response. The goal of this thesis 
was to devise a novel way to define the role of TgGCN5-B in Toxoplasma and begin to 
understand the role of acetylation of TgGCN5-B. 
      
Hypothesis and aims 
 
In Toxoplasma, precise control of gene expression is crucial for its complex life 
cycle and rapid proliferating stage, but this topic remains poorly understood. Toxoplasma 
lacks conventional transcription factors operating in other eukaryotes [3]. However, a 
rich but largely unexplored repertoire of chromatin remodelers and histone-modifying 
enzymes has been discovered in the parasites [4]. These findings led to the speculation 
that epigenetics and histone modification significantly contribute to the regulation of gene 
expression in Toxoplasma. Our preliminary data using a dominant-negative TgGCN5-B 
mutant parasite clone suggests that TgGCN5-B is important for parasite viability. 
Additionally, we have found that TgGCN5-B is acetylated in vivo, suggesting that its 
function may be regulated at a post-translational level. We hypothesize that TgGCN5-B 
regulates the expression of crucial genes in Toxoplasma and its function is 
regulated through lysine acetylation. This hypothesis will be examined by performing 
the following specific aims: 
Aim 1: Determine how expression of an inactive form of TgGCN5-B affects parasite 
viability.  
Aim 2: Study if lysine acetylation regulates the function of GCN5-B. 
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CHAPTER 2 
Materials and Methods 
 
Note: Biochemistry, proteomics, and ChIP-chip studies were performed in collaboration 
with Dr. Kami Kim’s laboratory at Albert Einstein College of Medicine. Generation of 
tagged AP2 transgenic parasites and reciprocal co-immunoprecipitations were 
performed in collaboration with Dr. Kevin Liu (Sullivan lab, IUSM). Additional assistance 
with parasite replication assays was provided by Dr. Vicki Jeffers (Sullivan lab, IUSM). 
The dominant-negative TgGCN5-B clone was generated by Dr. Stacy Dixon (Sullivan 
lab, IUSM). 
 
Parasite culture and methods 
 
All Toxoplasma lines (RH strain) were propagated in monolayers of human 
foreskin fibroblasts (HFFs) in Dulbecco modified Eagle’s medium (DMEM) supplemented 
with 1% heat-inactivated fetal bovine serum (Gibco/Invitrogen). Cultures were 
maintained in a humidified, 37°C incubator with 5% CO2. To isolate parasites for 
experiments, intracellular tachyzoites were harvested through syringe passage of 
infected host cells followed by filtration through a 3 micron filter [79]. Where designated, 
Shield-1 (CheminPharma), dissolved in ethanol, was added to culture medium. Plasmids 
were introduced into Toxoplasma via electroporation, subjected to drug selection (20 µM 
chloramphenicol or 1 µM pyrimethamine), and cloned by limiting dilution as previously 
described [61]. 
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Parasite assays 
 
The Toxoplasma doubling assay was performed by counting individual 
tachyzoites in at least 50 randomly chosen parasite vacuoles as previously described 
[62]. Parasite proliferation was also evaluated using the PCR-based B1 assay [42]. For 
each treatment, 1000 parasites were allowed to infect an HFF monolayer for designated 
time course. Genomic DNA from these infected cultures was purified using DNeasy® 
Blood & Tissue Kit (Qiagen) and used as template in quantitative real-time PCR to 
amplify the Toxoplasma B1 gene. Parasite motility, adhesion/invasion to host cells, and 
egress assays were performed as outlined in [63]. 
 
Generation of transgenic parasite lines  
 
Ectopic expression of inducible forms of TgGCN5-B. We constructed vectors that 
would express recombinant versions of TgGCN5-B fused to a destabilization domain (dd) 
and HA epitope tag at the N-terminal end (ddHA). Total RNA was purified from purified 
parasites using RNeasy® Plus Mini Kit (Qiagen) then made into cDNA with random 
primers using Omniscript® RT Kit (Qiagen). The TgGCN5-B coding sequence was 
amplified from cDNA, engineering an HA epitope (italics) and NsiI restriction site 
(underscored) at 5’ end and an AvrII restriction site at 3’ end (sense primer:  5’-
ATGCATTACCCGTACGACGTCCCGGACTACGCGGCGCCTTCAGAGTGTCCCAGCG
ACGCG; anti-sense primer: 5’-CCTAGGCTAGAAAAATGTCGGATGCTTCGCGC 
CCACAAGCCCCTCGTCTCC). The dd fragment was amplified from plasmid 
pLIC.2×HA-DD::DHFR construct (kindly provided by Dr. Michael White [64]), engineering 
a NdeI restriction site (underscored) at the 5’ end and NsiI and AvrII restriction sites 
(underscored) at the 3’ end (sense primer: 5’-CATATGAAAATGGCGGG 
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AGTGCAGGTGGAAACCATCTCC; anti-sense primer: 3’-CCTAGGATCGATATGCAT 
TTCCGGTTTTAGAAGCTCCACATCGAAGACGAGAGTGGC). The amplified dd 
fragment was cloned into a Toxoplasma ptubXFLAG::CAT expression vector, which 
contains a tubulin promoter and CAT minigene for chloramphenicol selection, using the 
NdeI and AvrII restriction sites [58], followed by insertion of the HA-TgGCN5-B coding 
sequence at the NsiI and AvrII sites. The QuikChange™ Site-Directed Mutagenesis Kit 
(Agilent Technologies) was used to create a point mutation (E703G) in the TgGCN5-B 
coding region in this construct (sense primer: 5’-CAGCAGAAATTCGCCGGCATCGCTT 
TCCTCGCG;anti-sense primer: 5’-CGCGAGGAAAGCGATGCCGGCGAATTTCTGCTG). 
Plasmids were linearized using NotI prior to transfection into parasites by electroporation. 
Endogenous tagging of AP2 factors. Genomic DNA from the 3’ end of AP2X-8 
(TGGT1_125480), AP2IX-7 (TGGT1_032510), or AP2X-5 (TGGT 1_068820) was 
amplified from parental strain RHΔKu80 and cloned into the pLIC.HA3.DHFR vector 
(kindly provided by Michael White) at the PacI site using methods described by Huynh 
and Carruthers, 2009 [65]. Primers for the genomic fragments were as follows. AP2IX-7 
(sense primer 5’-TACTTCCAATCCAATTTAATGCCGGCGGCATGAGCTTCAGTT; 
antisense 5’-TCCTCCACTTCCAATTTTAGCAAAGTCTTCGTCAACAACGAACTTGC). 
AP2X-5 (sense primer 5’-TACTTCCAATCCAATTTAATGCAGCTACACGACAGCGAC 
GGA; antisense 5’-TCCTCCACTTCCAATTTTAGCGGGCCAAAACGAGGAAGCGAG). 
AP2X-8 (sense 5’-TACTTCCAATCCAATTTAATGCAGCGCAGAAGCTGCAGAACC; 
antisense 5’-TCCTCCACTTCCAATTTTAGCTCCCCCCGCGCCTCTCAC). Fifty μg 
plasmid DNA of AP2IX-7HA, AP2X-5HA, and AP2X-8HA were linearized by NcoI, Bpu10I, 
or NsiI, respectively, and then electroporated into RHΔKu80 parasites. Following three 
passages under 1.0 µM pyrimethamine selection, parasites were cloned by limiting 
dilution. 
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Immunofluorescence assays 
 
Immunofluorescence assays (IFA) were performed as previously described [58]. 
Briefly, HFF monolayers grown on coverslips were inoculated with the designated 
parasite line, sometimes containing Shield-1 or EtOH vehicle. After removal of culture 
medium, infected HFFs were fixed in 3% paraformaldehyde for 10 min and then were 
permeabilized with 0.3% Triton X-100 for 10 min. For visualization of HA-fusion proteins, 
rat monoclonal anti-HA primary antibody (Roche #11867423001) was applied at 1:2000 
followed by goat anti-rat Alexa Fluor 488 secondary antibody at 1:2000 (Invitrogen #A-
11006). Nuclei were co-stained with 4',6-diamidino-2-phenylindole (DAPI). Samples 
were visualized using a Leica DMLB fluorescent microscope. 
 
Western blotting 
 
Analysis of Shield-based regulation of ddTgGCN5-B expressing parasites was 
performed by Western blot after resolving 50 µg parasite lysate on a 4-12% Tris-acetate 
polyacrylamide gradient gel (Invitrogen) and probing with 1:2000 rat anti-HA monoclonal 
antibody as the primary antibody (Roche #11867423001). Analysis of histones and 
tubulin used the following primary antibodies: rabbit polyclonal anti-H3 antibody (Abcam 
#ab1791, 1:2000), rabbit polyclonal antibodies against acetyl K9 (Millipore #06-942, 
1:2000), acetyl K14 (Millipore #06-911, 1:2000), acetyl H3K18 (Abcam #ab1191, 1:2000) 
and rabbit polyclonal antibody against Toxoplasma β-tubulin (kindly provided by Dr. 
David Sibley, 1:5000). Anti-rat or anti-rabbit antibodies conjugated with horseradish 
peroxidase (GE Healthcare) were used as secondary antibodies at 1:5000. The blots 
were visualized using Chemiluminescence Western Blot Substrate (Pierce). 
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Purification of TgGCN5-B complex 
 
The TgGCN5-B complex was purified from RH strain parasites stably transfected 
to ectopically express an Nt HAmyc-tagged form of full-length TgGCN5-B driven by the 
Toxoplasma tubulin (TUB1) promoter [58]. Large-scale tachyzoite cultures were grown in 
monolayers of HFF cells at 37°C for 42 hours post-infection. Prior to egress, culture 
medium was removed and the cell monolayers were washed once with PBS, scraped 
into cold PBS and then collected by centrifugation at 4°C for 10 min at 700xg. The cell 
pellets were resuspended in 25 ml cold PBS, and sequentially passed through 20/23/25-
guage needles in a 30 ml syringe to release intracellular parasites from the host cells. To 
prepare parasite nuclear extracts, 3×109 parasites were incubated 5 min on ice in lysis 
buffer A (0.1% [v/v] NP-40, 10 mM HEPES pH 7.4, 10 mM KCl, 10% [v/v] glycerol, 20 
mM sodium butyrate, plus protease inhibitors), and the nuclei were pelleted by 
centrifugation 6,000xg for 8 min at 4ºC. The parasite nuclei were then incubated 30 min 
at 4°C in lysis buffer B (0.1% [v/v] NP-40, 10 mM HEPES pH 7.4, 400 mM KCl, 10% [v/v] 
glycerol, 20 mM sodium butyrate, plus protease inhibitors) with rotation, and subjected to 
five freeze-thaw cycles followed by vortexing for 1 min at 4ºC before freezing. The 
nuclear extracts were clarified by centrifugation at 12,000xg for 30 min at 4ºC. The 
mixture of the clarified nuclear extracts (1 part) with lysis buffer A (2 parts) was used for 
co-immunoprecipitation. Nuclear extracts were incubated with mouse monoclonal anti-
HA-tag magnetic beads (µMACS Anti-HA Microbeads; Miltenyi Biotec) overnight at 4ºC 
with rotation. After the beads were washed 4 times with cold wash buffer 1 (150 mM 
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 8.0) and 
once with wash buffer 2 (20 mM Tris-HCl pH 7.5) by using µ Column (pre-washed with 
buffer containing 0.1% [v/v] NP-40, 10 mM HEPES pH 7.4, 150 mM KCl, plus protease 
inhibitors) in the magnetic field of the separator, the bound proteins were eluted from the 
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magnetic beads by applying 50 μl of Laemmli’s sample buffer (pre-heated to 95ºC) to the 
column. Eluted proteins were separated by SDS-PAGE (Any kD™ precast 
polyacrylamide gel; Bio-Rad), and stained with Coomassie blue (GelCode Blue Stain 
Reagent; Pierce). The entire length of each sample lane was systematically cut into 24 
slices and the gel slices were maintained in MilliQ water until trypsin digestion. 
 
Liquid chromatography coupled to mass spectrometry (LC/MS-MS)  
 
Proteins from a Coomassie-stained gel were reduced then alkylated with TCEP 
and iodoacetamide prior to digestion with trypsin. Trypsin (Sequencing grade, Promega) 
digestion was carried out for 1 hour at 50ºC using 10 ng/μl solution in 25 mM ammonium 
bicarbonate/0.1%ProteaseMax (Promega). The resulting digest was then diluted with 
2%Acetonitrile/2%TFA prior to LC-MS/MS analysis. Nanospray LC-MS/MS was 
performed on a LTQ linear ion trap mass spectrometer (LTQ, Thermo, San Jose, CA) 
interfaced with a Rapid Separation LC3000 system (Dionex Corporation, Sunnyvale, 
CA). Thirty-five μl of the sample was loaded on an Acclaim PepMap C18 Nanotrap 
column (5 µm, 100Å,/ 100 µm i.d. x 2cm) from the autosampler with a 50 µl sample loop 
with the loading buffer (2% Acetonitrile/water + 0.1% trifluoroacetic acid) at a flow rate of 
8 µl/min. After 15 minutes, the trap column was switched in line with the Acclaim 
PepMap RSLC C18 column (2 µm, 100 Å, 75 µm i.d. x 25 cm) (Dionex Corp). The 
peptides are eluted with gradient separation using mobile phase A (2% Acetonitrile/water 
+0.1% formic acid) and mobile phase B (80% acetonitrile/water + 0.1 % formic acid). 
Solvent B was increased from 2 to 35% over 40 min, increased to 90% over a 5-min 
period and held at 90% for 10 min at a flow rate of 300 nL/min. The 10 most intense ions 
with charge state from +2 to +4 determined from an initial survey scan from 300-1600 
m/z, were selected for fragmentation (MS/MS). MS/MS was performed using an isolation 
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width of 2 m/z; normalized collision energy of 35%; activation time of 30ms and a 
minimum signal intensity of 10000 counts. The dynamic exclusion option is enabled. 
Once a certain ion is selected once for MS/MS in 7 sec, this ion is excluded from being 
selected again for a period of 15 sec. 
Mgf files were created from the raw LTQ mass spectrometer LC-MS/MS data 
using Proteome Discoverer 1.2 (ThermoScientific). The created mgf files were used to 
search the Toxo_Human Combined database using the in-house Mascot Protein Search 
engine (Matrix Science) with the following parameters: trypsin 2 missed cleavages; fixed 
modification of carbamidomethylation (Cys); variable modifications of deamidation (Asn 
and Gln), pyro-glu (Glu and Gln) and oxidation (Met); monoisotopic masses; peptide 
mass tolerance of 2 Da; product ion mass tolerance of 0.6 Da. The final list of identified 
proteins was generated by Scaffold 3.5.1 (Proteome Software) with following filters: 99% 
minimum protein probability, minimum number peptides of 2 and 95% peptide 
probability.  
 
Immunoprecipitation of TgGCN5-B complexes from parasites containing HA-
tagged AP2 factors  
 
Parasites from AP2IX-7HA, AP2X-5HA, AP2X-8HA, and parental RHΔku80 lines 
were harvested in lysis buffer (150mM NaCl, 50mM Tris-Cl pH7.4, 0.1% NP-40) with 1x 
protein inhibitor cocktail (Sigma) and 1mM PMSF. The lysates were then sonicated and 
centrifuged to remove the insoluble fraction. Immunoprecipitations were performed using 
anti-HA high affinity matrix (Roche) and 300 μg total parasite protein. After overnight 
incubation at 4°C, the beads were washed 3x in lysis buffer and treated at 95°C for 10 
minutes to elute proteins. Eluted proteins were resolved by SDS-PAGE and analyzed by 
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western blot with anti-HA (1:2000), anti-GCN5B (1:500) and anti-β-tubulin (1:1000) 
antibodies.   
 
Quantitative reverse-transcriptase PCR (qRT-PCR) 
 
1.0 µg of total RNA purified from intracellular parasites was transcribed into 
cDNA using Omniscript® reverse transcriptase with oligo-dT primers according to the 
manufacturer’s protocol (Qiagen). qRT-PCR was performed in 25 µl volume reactions 
containing SYBR Green PCR Master Mix (Applied Biosystems), 0.5 mM of each forward 
and reverse primer (Table 2), and 1.0 µl of a 1:10 dilution of cDNA. Target genes were 
amplified using the 7500 Real-time PCR system and analyzed with relative quantification 
software (7500 software v2.0.1, Applied Biosystems). The ratio of mRNA levels in 
Shield-treated parasites versus EtOH-treated parasites was calculated using 
Toxoplasma β-tubulin as an internal control for normalization. Reactions were performed 
in triplicate and Student’s t-test was applied to RT-PCR data.  
 
 
Primer sequence(5'-3') Primer name 
AAACGCCACCTGCAGAAAAT TGME49_247690F 
TTGAGGCCGATGCCGATAT TGME49_247690R 
TTGGCACAGCGCATCAGTT TGME49_294550F 
TCGATCCACTCTGCCAAAGTC TGME49_294550R 
GGCGAACCTGACGATGATG TGME49_295760F 
CTTTCGGCGACTTGCAAAAT TGME49_295760R 
CTCTTGGCAAGCCGTACGTT TGME49_270840F 
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CCCCACACCGAACAGACTCT TGME49_270840R 
TACACGTCGCACGGAAAGG TGME49_290960F 
TGGCATCGTAGGACGTTGAA TGME49_290960R 
CCCCGCCAGGCAAGAG TGME49_253170F 
GAAATGGAGGAGACAGAGCAGAA TGME49_253170R 
GCATCAGCGCGTCATCCT TGME49_319560R 
CTCGGATCCCGATTCTCCTT TGME49_319560R  
GTCGGAGCAGCCAACACAGT TGME49_280500F 
CCCCCCACCTTTAGATTCAAG TGME49_280500R 
GGACGAGGCGGAATTGAAG TGME49_297060F 
TGTGCATGCGGCTTTCTTAT TGME49_297060R 
TTTTGCTTGGGATTCGAGGAT TGME49_289690F 
TGCAGGGTAACGATCAAAAAATG TGME49_289690R 
TCGACGAAGAGACAGGAAATGA TGME49_294200F 
CATGCGCTCCTGGATAAACA TGME49_294200R 
ACCTGTCGTGTGGTGTTTCTTCT TGME49_236210F 
GAAACCACACGCGAAACTGA TGME49_236210R 
Table 2. List of primers used in the RT-PCR.   
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CHAPTER 3 
Results 
 
Aim 1: Determine how expression of an inactive form of TgGCN5-B affects 
parasite viability.  
 
TgGCN5-B interacts with a large number of novel proteins 
 
Toxoplasma is unusual as an invertebrate, possessing two GCN5-family KATs. 
TgGCN5-A was shown to be dispensable for parasite replication in normal culture 
conditions, but TgGCN5-B appeared to be essential [57]. To gain insight into the role of 
TgGCN5-B in parasite physiology, we used parasites ectopically expressing 
recombinant TgGCN5-B with an N-terminal HA tag to define the KAT’s interactome. By 
virtue of the epitope tag, we performed biochemical purifications of the TgGCN5-B 
complex from nuclear fractions of intracellular tachyzoites. Proteins immunopurifying 
with TgGCN5-B are listed in Table 1. The identification of TgGCN5-B itself as well as the 
known interacting co-activator protein ADA2-A [57], highlights the fidelity of the 
purification. It has been noted before that Toxoplasma lacks homologues of most 
proteins found in the GCN5 complexes in other species [57]. In support this in silico 
finding, the majority of proteins purified with TgGCN5-B are novel interacting partners. 
Nearly half of the proteins comprising the TgGCN5-B complex are hypothetical, parasite-
specific proteins with unknown function. 
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Accession # Product Description 
TGME49_043440 TgGCN5-B* 
TGME49_017050 transcriptional co-activator ADA2-A* 
TGME49_120300 
SNF2 family N-terminal domain-containing 
protein 
TGME49_078440 
bromodomain, transcription regulatory 
protein SNF2, putative 
TGME49_058990 bromodomain-containing protein 
TGME49_076180 
bromodomain-containing KAT protein 
(TAF1/TAF250)* 
TGME49_094350 DEAD/DEAH box helicase, putative 
TGME49_118440 DEAH-box RNA/DNA helicase, putative 
TGME49_003220 ATP-dependent RNA helicase, putative 
TGME49_011690 ATP-dependent helicase, putative 
TGME49_031970 pre-mRNA splicing factor PRP8, putative* 
TGME49_023390 
sec63 domain-containing DEAD/DEAH 
box helicase, putative 
TGME49_030960 splicing factor 3B subunit 3, putative 
TGME49_058240 
chromodomain helicase DNA binding 
protein, putative 
TGME49_109250 AT hook motif-containing protein* 
TGME49_110900 AP2XI-2 
TGME49_090630 AP2IX-7* 
TGME49_047700 AP2XII-4* 
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TGME49_014960 AP2X-8* 
TGME49_013900 
regulator of chromosome condensation, 
putative 
TGME49_065840 
200 kDa antigen, SMC (structural 
maintenance of chromosomes) 
TGME49_055340 TPR domain-containing protein 
TGME49_091930 
nucleolar phosphoprotein nucleolin, 
putative* 
TGME49_064660 
SRS domain-containing, N-
acetylglucosamine-phosphate mutase, 
putative 
TGME49_106400 hypothetical protein, conserved* 
TGME49_108890 hypothetical protein, conserved (Spt6) 
TGME49_071740 hypothetical protein (PHD domain)* 
TGME49_011010 
hypothetical protein, SANT domain myb-
like 
TGME49_074180 hypothetical protein 
TGME49_114410 hypothetical protein 
TGME49_025910 hypothetical protein 
TGME49_053750 hypothetical protein* 
TGME49_029790 hypothetical protein 
TGME49_105340 hypothetical protein 
TGME49_080590 hypothetical protein* 
TGME49_065240 hypothetical protein* 
TGME49_105790 hypothetical protein 
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Table 1. Proteins associating with TgGCN5-B in Toxoplasma tachyzoites.  
An asterisk denotes the protein was previously detected as acetylated. Shaded entries 
represent a core set of proteins commonly pulled down in independent purifications of 
TgGCN5-B, AP2IX-7, and AP2X-8. 
 
As GCN5 KATs lack DNA-binding domains, they are believed to be recruited by 
DNA-bound transcription factors. Consistent with this idea, TgGCN5-B was found in 
association with four putative AP2 transcription factors, AP2IX-7, AP2X-8, AP2XI-2, and 
AP2XII-4. Other TgGCN5-B-interacting proteins with potential DNA-binding domains 
include an AT-hook protein (TGME49_109250) and a myb-like protein 
(TGME49_011010). Two additional proteins, TGME49_013900 and TGME49_065840, 
have predicted roles in organizing and segregating chromosomes. GCN5 activities are 
typically coordinated with those of SWI/SNF complexes, and we detected two 
independent SWI/SNF ATPases associated with the TgGCN5-B complex 
(TGME49_120300 and TGME49_078440). A surprising number of ATP-dependent 
helicases and other components associated with pre-mRNA splicing were also found in 
association with TgGCN5-B (Table 1).  
TGME49_032680 hypothetical protein* 
TGME49_026660 hypothetical protein 
TGME49_039300 hypothetical protein 
TGME49_053370 hypothetical protein 
TGME49_070930 hypothetical protein 
TGME49_041850 hypothetical protein* 
TGME49_029750 hypothetical protein 
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Four proteins, including TgGCN5-B itself, contain bromodomains, which 
recognize acetylated lysine residues [66]. Another bromodomain protein is 
TAF1/TAF250, a component of the TFIID complex that also possesses KAT activity [67]. 
The detection of TAF1/TAF250 is consistent with GCN5 complexes interacting with the 
transcriptional pre-initiation complex [68]. Sixteen of the proteins pulled down with 
TgGCN5-B were detected as acetylated in a previous study (denoted with asterisk in 
Table 1), including TgGCN5-B itself, the ADA2-A co-activating protein, TAF1/TAF250, 
and most of the AP2 factors. These proteins are likely to be acetylated by TgGCN5-B or 
TAF1/TAF250. The precise role of these acetylated lysines remains to be determined; 
however, the presence of four bromodomain modules in the complex supports the idea 
that they participate in intracomplex protein-protein interactions [69]. 
The finding that AP2 factors work in conjunction with KAT complexes to alter 
transcription is of particular relevance. Transcription factors such as GCN4 in yeast are 
known to recruit GCN5 [70], but it has not been established, even in plants, that AP2 
factors can do the same. To validate the interactions between TgGCN5-B and AP2 
factors, we endogenously tagged AP2IX-7 and AP2X-8 with a C-terminal 3xHA tag. 
Reciprocal co-immunoprecipitation of each AP2 factor pulled down TgGCN5-B and 
many of the other proteins in the TgGCN5-B complex. Proteins that were pulled down 
consistently in all three purifications are shaded in Table 1. To further confirm the 
interaction and specificity between TgGCN5-B and these AP2 factors, we performed 
Western blots for TgGCN5-B in AP2IX-7HA and AP2X-8HA immunoprecipitates. We also 
endogenously tagged AP2X-5, an AP2 factor that was not seen in the TgGCN5-B 
complex, to serve as a control. As shown in Figure. 3(A) and (B) top left panel, the three 
AP2s are properly expressed. Figure. 3(B) top right panel shows that the IPs were 
successful. Consistent with the reciprocal IP-MS analysis, TgGCN5-B was detected in a 
Western blot of HA-immunoprecipitated AP2IX-7HA and AP2X-8HA, but not AP2X-5HA. 
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Collectively, these results demonstrate specific interactions between TgGCN5-B and 
AP2IX-7 and AP2X-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A 
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HA 
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DIC 
merged 
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Figure 3. Independent confirmation of the in vivo interaction of TgGCN5-B with 
endogenously HA-tagged AP2IX-7 and AP2X-8. 
 (A) AP2IX-7HA, AP2X-8HA, and AP2X-5HA parasites were subjected to 
immunofluorescence assays using an anti-HA antibody (Green), and the DNAs were 
stained by DAPI (blue). Scale bar = 2 µm. (B) Immunoprecipitations using an anti-HA 
antibody were performed on parasite lysates made from AP2IX-7HA, AP2X-8HA, and 
AP2X-5HA parasites, as well as the parental RHΔku80 line. The immunoprecipitated 
complexes were analyzed by Western blot using antibodies recognizing HA-tag, 
TgGCN5-B, or β-tubulin. Arrowheads mark the expected bands with predicted molecular 
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weights (in kDa) as follows:  AP2IX-7: 268, AP2X-5: 220, AP2X-8: 399, GCN5-B: 110, 
and β-tubulin: 51.   
 
Genome-wide localization of TgGCN5-B 
 
We also used parasites expressing the HA-tagged TgGCN5-B to perform a 
genome-wide ChIP-chip analysis. Immunoprecipitated DNA associated with TgGCN5-B 
was identified following hybridization to custom Nimblegen microarrays that tile the entire 
Toxoplasma genome. TgGCN5-B was detected at ~14% of tachyzoite genes, nearly half 
of which are annotated as hypothetical genes of unknown function in the ToxoDB 
(Figure. 4). Most of the genes coinciding with TgGCN5-B localization are associated with 
signaling and gene expression (18%), followed closely by genes involved in translation 
and protein processing (15%). TgGCN5-B was also found at a moderate number of 
metabolic genes (11%).  
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Figure 4. Genome-wide localization of TgGCN5-B.  
TgGCN5-B was observed within the coding sequence of ~700 genes and the promoter 
region of ~30 genes. The functional breakdown of TgGCN5-B-associated genes displays 
a wide range of biological functions (241 hypothetical genes are not shown).  
 
TgGCN5-B was detected in gene bodies as well as promoter regions, consistent 
with recent studies showing a role for GCN5 in transcriptional elongation by promoting 
nucleosome eviction [71]. Overall, the ChIP-chip results establish that TgGCN5-B is 
present within or near the loci of at least 14% of tachyzoite genes involved in a wide 
variety of cellular functions. 
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Expression of catalytically inactive TgGCN5-B arrests replication  
 
In order to better define the role of TgGCN5-B in Toxoplasma, we attempted to 
generate a gene knockout. Repeated attempts to disrupt or replace TgGCN5-B using 
homologous recombination in haploid type I RH strain tachyzoites have not been 
successful, in contrast TgGCN5-A could be knocked out using the same approach. More 
recent attempts to knockout the TgGCN5-B locus in a ∆ku80 background also failed to 
generate viable parasites. Considered together, these results suggest that TgGCN5-B 
may be essential in tachyzoites. 
To address this hypothesis, we pursued an inducible dominant-negative strategy. 
As TgGCN5-B appears to work in a multi-subunit complex, this protein is a good 
candidate for a dominant-negative strategy whereby an enzymatically dead version 
would sequester essential interacting proteins from endogenous TgGCN5-B. Previous 
graduate student Stacy Dixon generated clonal parasites in an RH background 
expressing a catalytically inactive form of TgGCN5-B (mutated glutamic acid 703 to 
glycine, E703G [72] fused to a destabilization domain and HA tag (ddHA) at the N-
terminus. As a control, we also generated a clone expressing wild-type (WT) TgGCN5-B 
in the same fashion. Expression of the ddHAGCN5-B fusion proteins was driven by the 
Toxoplasma tubulin promoter. In vitro KAT assays using purified ddHAGCN5-B proteins 
confirm the E703G mutation ablates enzymatic activity (data not shown).  
The destabilization domain directs its fusion partner to the proteasome for rapid 
degradation, but this can be averted by adding Shield ligand to the culture medium. 
Fusion of ddHA to the N-terminus of TgGCN5-B or TgGCN5-B(E703G) allowed their 
ectopic expression to be regulated via Shield, as assessed in IFAs and immunoblots 
using anti-HA (Figure. 5). Addition of ddHA did not disrupt the expected nuclear 
localization of WT or mutant TgGCN5-B. No difference was observed between parental 
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wild-type parasites and those ectopically expressing ddHAGCN5-B protein at any 
concentration of Shield (Figure. 6A). In contrast, parasites induced to express ddHAGCN5-
B(E703G) underwent rapid growth arrest in 48 hours with only 10 nM Shield (Figure. 
6B). Similar results were obtained when we used a PCR-based assay (5) to measure 
parasite replication (data not shown). 
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Figure 5. Inducible expression of ectopic ddHAGCN5-B and ddHAGCN5-B(E703G) in 
Toxoplasma.  
Immunofluorescence assays using an anti-HA antibody on (A) ddHAGCN5-B and (B) 
ddHAGCN5-B(E703G) parasites, cultured in the presence or absence of 500nM Shield. 
Anti-HA signal is shown in green and nucleic acid staining with DAPI is depicted in blue. 
Scale bar = 2 µm. C. Western blots of ddHAGCN5-B (left) and ddHAGCN5-B(E703G) (right) 
parasite lysates using anti-HA antibody shows stabilization of the respective dd-fusion 
protein after 48 hr incubation with 500nM Shield. 
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Figure 6. Induced expression of ddHAGCN5-B(E703G) arrests parasite replication.  
Doubling assays were performed to assess growth of (A) ddHAGCN5-B and (B) 
ddHAGCN5-B(E703G) parasites. Intracellular parasites were physically released from host 
cells and an equal number of parasites were allowed to infect fresh HFF monolayers. 
The infected cultures were subjected to the indicated Shield concentrations for 48 hr. 
Parasite proliferation was monitored by quantifying the numbers of parasites in 50 
random vacuoles. 
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Reduced histone acetylation in TgGCN5-B DN parasites 
 
We considered that the replication arrest observed in ddHAGCN5-B(E703G) 
parasites may be due to a reduction in histone acetylation, which in turn would lead to 
dysregulation of the transcriptome. To assess this possibility, we analyzed the 
acetylation level of individual lysine residues in histone H3, the preferred substrate of 
GCN5 family KATs, purified from Shield- versus vehicle-treated ddHAGCN5-B or 
ddHAGCN5-B(E703G) expressing parasites. Acetylation levels of lysines K9 and K14 
were decreased in only the parasites expressing ddHAGCN5-B(E703G) protein (Figure. 
7). The decreased acetylation was not an artifact of decreased H3 expression, and other 
acetylated proteins like tubulin, were unaffected by the induction of the ddHAGCN5-
B(E703G). Interestingly, the acetylation status of H3K18 was not affected, which may be 
explained by the fact that TgGCN5-A, which would not be attenuated by the expression 
of ddHAGCN5-B(E703G), has an exquisite affinity for this particular lysine residue on H3 
(20). These data indicate that the expression of ddHAGCN5-B(E703G) protein diminishes 
acetylation on histone H3. 
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Figure 7. Reduced histone H3 acetylation in ddHAGCN5-B(E703G) parasites.  
ddHAGCN5-B parasites and ddHAGCN5-B(E703G) parasites were cultured in the presence 
of 500 nM Shield for 48 hr. Equivalent amounts of parasite lysate obtained from Shield- 
vs. vehicle-treated parasites was analyzed by Western blotting using antibodies 
recognizing various acetylated lysine residues of histone H3 (acetylated lysine 9, 14, and 
18). Anti-HA was used to monitor protein stabilization. Antibodies to total H3 show that 
induced stabilization of each GCN5-B protein did not alter overall H3 protein levels. 
Western analysis of β-tubulin levels served as an additional loading control. 
Densitometry was used to compare relative levels of each histone acetylation mark 
between the Shield- and vehicle-treated parasites. Data is normalized to β-tubulin. 
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Expression of TgGCN5-B associated genes in ddHAGCN5-B(E703G) parasites 
 
Acetylation of H3K9 and K14 is required for recruitment of TFIID[73], therefore 
reduced histone acetylation levels should lead to inactivation of gene expression. 
Attempts were made to perform microarray analysis of ddHAGCN5-B and ddHAGCN5-
B(E703G) under Shield versus vehicle conditions, but it proved challenging to obtain 
sufficient parasite RNA from the arrested ddHAGCN5-B(E703G) parasites. We then 
attempted a more targeted approach to analyze genes that were strongly associated 
with TgGCN5-B in the ChIP-chip dataset. Primers were designed to amplify selected 
mRNAs in ddHAGCN5-B or ddHAGCN5-B(E703G) parasites in the presence or absence of 
Shield (Table 2). Another set of mRNAs from genes that did not associate with TgGCN5-
B was included as a control. Virtually no changes in mRNA levels were detected in 
ddHAGCN5-B parasites regardless of whether TgGCN5-B was detected at the gene locus 
(Table 2). However, expression levels of mRNAs in ddHAGCN5-B(E703G) parasites were 
clearly altered. Four out of 6 genes associated with TgGCN5-B had lowered mRNA 
levels in the ddHAGCN5-B(E703G) parasites following Shield treatment (Table 2). Two 
other genes tested showed increased mRNA levels. Genes that were not associated 
with TgGCN5-B generally exhibited no significant difference in mRNA levels in the 
ddHAGCN5-B(E703G) parasites following Shield treatment, however one gene tested 
showed higher mRNA levels and another showed lower mRNA levels (Table 3). While 
there are exceptions, the results show a general trend that is consistent with the idea 
that the decreased acetylation observed in ddHAGCN5-B(E703G) parasites leads to 
decreased transcription of TgGCN5-B-associated genes. The dysregulation of gene 
expression induced by the accumulation of ddHAGCN5-B(E703G) protein may contribute 
to the arrest in parasite replication. 
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Table 3. Expression levels of select mRNAs in ddHAGCN5-B and ddHAGCN5-
B(E703G) parasites.  
Gene ID 
Product 
Description  
ddHAGCN5-
B 
ddHAGCN5-
B(E703G) 
GCN5-B localizes on coding region 
TGME49_247690 
phospholipid-
translocating P-
type ATPase 1.2±0.2 1.4±0.1 
TGME49_294550 
dynein heavy 
chain  1.1±0.2 0.4±0.1 
TGME49_295760 
calcium-
dependent protein 
kinase CDPK4A 0.9±0.3 0.5±0.0 
TGME49_270840 
poly(ADP-ribose) 
polymerase 
catalytic domain-
containing protein  1.0±0.2 0.6±0.0 
TGME49_290960 
pyruvate 
phosphate 
dikinase 0.8±0.1 1.3±0.1 
TGME49_253170 
zinc 
carboxypeptidase, 
putative 1.1±0.1 0.3±0.1 
GCN5-B does not localize on gene locus 
TGME49_319560  
microneme 
protein MIC3  1.1±0.2 1.3±0.3 
TGME49_280500 
inorganic anion 
transporter 0.9±0.2 0.5±0.3 
TGME49_297060 
phosphoglycerate 
mutase PGMII  1.0±0.3 1.4±0.4 
TGME49_289690 
glyceraldehyde-3-
phosphate 
dehydrogenase 
GAPDH1  1.0±0.3 0.8±0.3 
TGME49_294200 
glucose-6-
phosphate 1-
dehydrogenase 1.2±0.3 1.3±0.5 
TGME49_236210 
mitochondrial 
processing 
peptidase 1.3±0.3 2.3±0.4 
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Values represent fold-change of mRNA levels in parasites treated with Shield for 48 
hours relative to vehicle control. The fold change normalized to tubulin and the 
expression level of each gene in EtOH control was set as 1. Student’s t-test was 
performed and p values were <0.05.   
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Aim 2: Study if lysine acetylation regulates the function of GCN5-B. 
 
GCN5-B is acetylated at K857 of ADA2 binding domain 
 
To establish whether GCN5-B is acetylated in vivo, GCN5-B acetylation status in 
Shield-treated ddHAGCN5-B or ddHAGCN5-B(E703G) expressing parasites was analyzed 
by Western blotting using antibody anti-acetyl-Lys. ddHAGCN5-B or ddHAGCN5-B(E703G) 
was immunoprecipitated from parasites using specific anti-HA high affinity matrix and 
probed by Western blotting. ddHAGCN5-B is recognized by the anti-acetyl-Lys antibody, 
suggesting that TgGCN5-B is acetylated in  vivo (Figure. 8). However, ddHAGCN5-
B(E703G) is not recognized by the anti-acetyl-Lys antibody, indicating that TgGCN5-B 
may be subject to autoacetylation.  It is possible, however, that endogenous TgGCN5-B 
in the ddHAGCN5-B(E703G) expressing parasites may acetylate ddHAGCN5-B(E703G). 
Acetylome data from our lab reveals four lysine acetylation sites on TgGCN5-B (Figure. 
9) [16]. These four acetylation sites are unique to Toxoplasma. Interestingly, one of the 
acetylation sites, K857, is within the putative ADA2 binding domain.  
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Figure 8. GCN5-B is acetylated in vivo and the catalytic inactive version of protein 
is barely acetylated.  
ddHAGCN5-B parasites and ddHAGCN5-B(E703G) parasites were cultured in the presence 
of 500 nM Shield for 48 hr. Equivalent amounts of parasite lysate obtained from Shield- 
vs. vehicle-treated parasites was used for immunoprecipitation with anti-HA high affinity 
matrix. Protein from parental wild-type RH parasites was included as a negative control. 
The acetylation level of the products was analyzed by Western blotting using antibody 
that recognizes acetylated lysines (α-K(Ac)). The lower panel shows that the same 
amount of immunoprecipitated proteins were used in the immunoblots.  
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Figure 9. Acetylation sites on TgGCN5-B.  
The acetylated lysine sites identified in our Toxoplasma acetylome study are marked in 
yellow [16]. K857 is within the putative ADA2 binding domain of TgGCN5-B. K989, K997, 
K1027 at the C-terminus of TgGCN5-B are also acetylated. PCAF, a homolog of 
TgGCN5-B in humans, is also suggested to be acetylated at the ADA2 binding domain 
(highlighted green) [14].  
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Acetylation of K857 is required for proper TgGCN5-B complex formation 
 
To study if acetylation on K857 is required for protein-protein interactions, we 
mutated K857 to arginine (K857R) and assessed the impact on the TgGCN5-B 
interactome. Arginine conserves the charge of lysine, but cannot be acetylated. HAGCN5-
B parasites and HAGCN5-B(K857R) parasites, each ectopically expressing the 
recombinant protein, were used to purify the TgGCN5-B complex. The immunopurified 
proteins for each are listed in Table 4. The complex for HAGCN5-B was analyzed in aim 1. 
The data shows that HAGCN5-B(K857R) still binds with ADA2-A, as observed for 
HAGCN5-B. This data indicates that K857 acetylation does not affect the TgGCN5-B 
association with ADA2-A, although it should be noted that the minimal ADA2-A 
interaction domain has not been mapped. Interestingly, the K857R mutation had a 
profound impact on the recruitment of other subunits to the complex. For example, 
HAGCN5-B was found in association with four putative AP2 transcription factors, AP2IX-7, 
AP2X-8, AP2XI-2, and AP2XII-4, which are suggested to recruit TgGCN5-B to the 
transcriptional machinery. In contrast, HAGCN5-B(K857R) fails to associate with the AP2 
proteins. In fact, only two proteins in addition to ADA2-A continued to be pulled down 
with HAGCN5-B(K857R): the AT hook protein and a PHD finger protein. These results 
show that acetylation at K857 plays an important role in TgGCN5-B complex formation.  
 
 
 
 
Table 4. HAGCN5-B(K857R) complex in Toxoplasma.  
Please refer Table 1 from Aim1 for HAGCN5-B complex.  
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Acetylation of K857 is not required for nuclear localization and catalytic activity 
 
We also determined whether acetylation of K857 could affect acetyltransferase 
activity or protein localization of TgGCN5-B.  To test the acetyltransferase activity of 
TgGCN5-B, a standard in vitro HAT assay was performed using recombinant histone H3 
as substrate. Either immune purified HAGCN5-B or HAGCN5B(K857R) was reacted with 
acetyl-CoA and histone H3 substrate. Following the incubation time, the KAT assay 
reaction was resolved on SDS-PAGE for immunoblotting with anti-acetyl-H3 (Figure. 10). 
The results show that the same amount of HAGCN5-B and HAGCN5B(K857R) was 
applied for each KAT assay and that they both acetylate H3. This data suggests K857 
acetylation is not required for TgGCN5-B KAT activity. Immunofluorescence assays was 
used to reveal the localization of HAGCN5-B and HAGCN5B(K857R) (Figure. 11). The 
results show that HAGCN5-B and HAGCN5B(K857R) have the same nuclear localization. 
These experiments suggest that K857 acetylation does not affect nuclear localization of 
TgGCN5-B.  
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Figure 10. KAT assay of HAGCN5-B and  HAGCN5-B(K857R).  
Immunoprecipitations using an anti-HA antibody were performed on parasite lysates 
made from HAGCN5-B and  HAGCN5-B(K857R) parasites. The KAT assay reaction 
includes either  HAGCN5-B or  HAGCN5-B(K857R), histone H3, and acetyl-CoA. An 
equivalent amount of parental strain RH was used as a negative control. Western 
blotting of KAT assays was performed with antibody to specific acetylated (Ac) H3 lysine 
residues.  
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Figure 11. Nuclear localization of HAGCN5-B and  HAGCN5-B(K857R). 
Immunofluorescence assays using an anti-HA antibody on HAGCN5-B and  HAGCN5-
B(K857R) parasites. Anti-HA signal is shown in green and nucleic acid staining with 
DAPI is depicted in blue. scale bar = 2um. 
 
C-truncated TgGCN5-B has altered localization 
 
To explore if there is a functional role associated with the three acetylated lysines 
at C-terminus of TgGCN5-B (K989, K997, K1027) a parasite line was generated that 
expresses HAGCN5-B∆988-1033, which lacks the final 45 amino acid C-terminus 
fragment containing the three acetylated lysines. Immunofluorescence assays were 
performed to reveal the localization of HAGCN5-B∆988-1033, with HAGCN5-B as control 
(Figure. 12). The results show an altered localization of HAGCN5-B∆988-1033 compared 
to HAGCN5-B. HAGCN5-B localizes clearly to the parasite nucleus. However, HAGCN5-
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B∆988-1033 localizes in a distinct, punctate pattern that appears to extend throughout 
the whole parasite. Further study is needed to determine if this localization phenotype is 
associated with impaired function of acetylated lysines or some other element in the C-
terminal tail of TgGCN5-B. 
 
 
Figure 12. Altered localization of HAGCN5-B∆988-1033. 
Immunofluorescence assays using an anti-HA antibody on HAGCN5-B and  HAGCN5-
B∆988-1033 parasites. Anti-HA signal is shown in green and nucleic acid staining with 
DAPI is depicted in blue. Scale bar = 2um. 
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CHAPTER 4 
Discussion and Future direction 
 
Aim 1: Determine how expression of an inactive form of TgGCN5-B affects 
parasite viability.  
 
The objective of this study was to gain a better understanding of the role played 
by the second GCN5 KAT in Toxoplasma parasites through biochemical purification of 
associating proteins, ChIP-chip analyses, and the generation of mutants. Our findings 
reveal that TgGCN5-B interacts with a large number of novel proteins and is enriched at 
genes involved in transcription, translation, and metabolism. Consistent with previous 
failures to knockout TgGCN5-B, inducible expression of a catalytically dead version 
acted like a dominant-negative mutant and displayed replicative arrest, supporting the 
conclusion that TgGCN5-B is essential in tachyzoites. 
The TgGCN5-B interactome is remarkably unique and includes putative parasite-
specific transcription factors. A high-throughput yeast two-hybrid approach previously 
identified the single Plasmodium falciparum GCN5 to be the most interconnected protein 
in the parasite integrating chromatin modification, transcriptional regulation, mRNA 
stability, and ubiquitination (23). The discovery of AP2 factors in the TgGCN5-B 
interactome prompted us to re-examine the PfGCN5 data, since this analysis was done 
prior to the identification of AP2 domains. PfGCN5 interacts with two predicted AP2 
factors, PF3D7_1007700 and PF3D7_0802100. It is not possible at the present time to 
discern if the AP2s interacting with TgGCN5-B are orthologous. Interestingly, no other 
PfGCN5-interacting proteins cross-reference to the TgGCN5-B interacting proteins. This 
may be produced by the different techniques that were used (yeast two-hybrid using only 
the N-terminal extension of PfGCN5 as bait versus biochemical purification of TgGCN5-
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B), or could indicate that GCN5 complexes between apicomplexan species have 
significantly diverged. In support of this conclusion, the lengthy N-terminal extensions 
between PfGCN5 and TgGCN5-B share no homology. Another possibility is that the 
PfGCN5 complex may be more analogous to TgGCN5-A, whose interactome has yet to 
be resolved. 
It is well-established that histone acetylation complexes generally aggregate at 
gene promoters, but the considerable proportion of TgGCN5-B located within gene 
bodies is not without precedent. Govind et al reported that yeast GCN5 plays a role in 
transcriptional elongation by promoting histone eviction. Interestingly, a Spt6 homologue 
was purified with the TgGCN5-B complex, a protein that has been implicated in 
transcription elongation through binding of RNA polymerase II [74]. In other species, 
GCN5 has also been shown to play a role in co-transcriptional splicing [75]. The 
disproportionate number of pre-mRNA splicing components that we identified in the 
TgGCN5-B complex might be suggestive of additional roles for TgGCN5-B in splicing. It 
is possible that TgGCN5-B forms multiple complexes and contributes to an assortment 
of cell biological functions. While our data clearly shows that histone acetylation is 
decreased in the dominant-negative clone, we cannot rule out that the arrest in parasite 
replication is solely due to dysregulation of gene expression. Complicating matters is the 
recent observation that lysine acetylation is widespread on hundreds of non-histone 
proteins [69]. It is conceivable that TgGCN5-B has non-histone substrates and 
decreased efficiency in acetylation of those substrates contributes to the replication 
arrest in the dominant-negative parasites.  
Toxoplasma is unique as a lower eukaryote to possess a pair of GCN5 KATs. 
Studies to date suggest that these two TgGCN5 KATs have non-redundant functions. 
TgGCN5-B was not sufficient to compensate for a lack of TgGCN5-A, which is required 
for adequate responses to alkaline stress [42]. Similarly, TgGCN5-A is not able to 
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compensate when the function of TgGCN5-B is attenuated through expression of a 
dominant-negative version. Our findings suggest that pharmacological inhibition of 
TgGCN5-B or disruption of the TgGCN5-B complex may be novel avenues for therapy 
against toxoplasmosis. 
 
Aim 2: Study if lysine acetylation regulates the function of TgGCN5-B. 
 
The objective for Aim 2 was to investigate the consequences of lysine acetylation 
on TgGCN5-B protein. Acetylation is an important post-translational modification that 
regulates biological activities of protein by affecting protein-protein interaction, enzyme 
activity, and protein localization. TgGCN5-B is acetylated in vivo and this modification 
occurs at four lysines on the protein, K857, K989, K997, and K1027. K857 is within the 
putative ADA2 binding domain, while the other three lysines are at C-terminus of 
TgGCN5-B. The K857 to R mutation conserves the charge of lysine but cannot be 
acetylated. Our results suggest that HAGCN5-B associates with four putative AP2 
transcription factors (AP2IX-7, AP2X-8, AP2XI-2, AP2XII-4) and other proteins with 
important roles in control of transcription (discussed in Aim 1). However, the K857 to R 
mutation remarkably caused TgGCN5-B to lose its ability to associate with AP2s and 
most other subunits in the complex. One possible scenario that explains this data is that 
this acetylated lysine is crucial for the binding of another protein that helps to nucleate 
the majority of the TgGCN5-B complex. Alternatively, acetylated K857 of TgGCN5-B 
might regulate complex formation through an interaction with its own bromodomain, thus 
resulting in a structural change that favors association of AP2s and other subunits. 
Interestingly, the K857R mutation does not affect the association between TgGCN5-B 
and its co-activator protein ADA2-A, even though K857 lies within the putative ADA2 
binding domain. As the precise ADA2-binding domain has not been defined, we cannot 
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rule out that K857 is actually outside of the ADA2-binding domain. It is also possible that 
acetylation of K857 induces the disassociation of TgGCN5-B and ADA2-A, and 
deacetylation leads to their association. The IFA analysis showed that the effect on 
complex formation in the K857 mutant is not due to mislocalization of the mutant 
TgGCN5-B protein.          
HAGCN5-B∆988-1033, lacking the final 45 amino acids of TgGCN5-B, has a 
localization phenotype. HAGCN5-B localizes clearly to the nucleus, however, HAGCN5-
B∆988-1033 has a more punctate and diffuse localization throughout the parasite body. 
This C-terminal region is lacking a cluster of three acetylated lysines, K989, K997 and 
K1027. To further determine of any of the acetylated lysines at C-terminus have a 
functional role of protein localization, each of them should be mutated and studied 
individually. Other elements within this 45 amino acid region may also account for the 
differential localization. For example, there might be a novel type of nuclear localization 
signal at C-terminus of TgGCN5-B or other PTMs might occur here that contribute to 
nuclear localization.  
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